Presentation is loading. Please wait.

Presentation is loading. Please wait.

N1 decoys that block JAG elevate sVEGFR1/sFLT1.

Published byBrianne Tyler Modified over 5 years ago

Similar presentations

Presentation on theme: "N1 decoys that block JAG elevate sVEGFR1/sFLT1."— Presentation transcript:

1 N1 decoys that block JAG elevate sVEGFR1/sFLT1.
N1 decoys that block JAG elevate sVEGFR1/sFLT1. A, HEY1, HEY2, HEYL, and HES1 qRT-PCR of N1 decoys or JAG1 knockdown (KD) HUVECs. B–D, VEGF receptor qRT-PCR and flow cytometry of N1 decoys or JAG1 KD HUVECs. E, soluble VEGFR1 (sVEGFR1/sFLT1) qRT-PCR of N1 decoys or JAG1 KD HUVECs. A to E, data, as ± SD; *, P < F, soluble VEGFR1/sFLT1 ELISA presented as ± SD; *, P < G, VEGFR1 staining of Mm5MT-FGF4 tumor sections; scale bars, 30 μm. H, quantitation of the percentage of the mean VEGFR1–positive area; **, P < (n = 3). Thaned Kangsamaksin et al. Cancer Discovery 2015;5: ©2015 by American Association for Cancer Research

Download ppt "N1 decoys that block JAG elevate sVEGFR1/sFLT1."

Similar presentations

Glioma-derived soluble factor(s) enhance IL-10 signaling.

Glioma-derived soluble factor(s) enhance IL-10 signaling.
VEGF gene expression in HPMVEC and VEGF protein levels in CM

VEGF gene expression in HPMVEC and VEGF protein levels in CM
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.
Prmt7 deficiency causes a fiber-type switch toward glycolytic.

Prmt7 deficiency causes a fiber-type switch toward glycolytic.
Immunologic responses after the MN-mediated cancer immunotherapy.

Immunologic responses after the MN-mediated cancer immunotherapy.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Microarray analysis of phospho-Twist1–responsive genes.

Microarray analysis of phospho-Twist1–responsive genes.
Quantitative PCR of CRTAC1 (white columns) and WASF1 (black columns) loci in germ line DNA (A), glomus tumor no. 1 (B), and glomus tumor no. 3 (C) from.

Quantitative PCR of CRTAC1 (white columns) and WASF1 (black columns) loci in germ line DNA (A), glomus tumor no. 1 (B), and glomus tumor no. 3 (C) from.
Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.
Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.

Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.
Epithelial loss of TβRII results in increased Th17 cell development.

Epithelial loss of TβRII results in increased Th17 cell development.
2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.

2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.
CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.
Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.
mpJX-594 effects on tumor burden and leukocyte influx.

mpJX-594 effects on tumor burden and leukocyte influx.
Figure 2 P2Y12 expression is upregulated in M2-polarized human microglia(A, B) Using TaqMan quantitative real-time PCR, P2Y12 expression was measured in.

Figure 2 P2Y12 expression is upregulated in M2-polarized human microglia(A, B) Using TaqMan quantitative real-time PCR, P2Y12 expression was measured in.
Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Similar presentations

Ads by Google